Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.

Arzneimittel-Forschung ·Vol. 35 ·No. 4 ·1985-00-00 ·Pages 707-12

Geisen K, Hitzel V, Okomonopoulos R, Pünter J, Weyer R, Summ HD

Abstract

Specific binding of 3H-glibenclamide (HB 419) is observed with membranes from rat cerebral cortex and rat beta-cell tumor. 3H-Glibenclamide binding is of high affinity, reversible, saturable, and can be displaced by oral antidiabetics of different structural types. Half maximal inhibition of binding correlates with the hypoglycemic action of the compounds.

MeSH Terms

Animals Binding, Competitive/drug effects Blood Glucose/metabolism Cerebral Cortex/metabolism Female Glyburide/metabolism Hypoglycemic Agents/pharmacology Insulinoma/metabolism Male Membranes/metabolism Neoplasm Transplantation Pancreatic Neoplasms/metabolism Rabbits Rats Rats, Inbred Strains Receptors, Drug/metabolism Sulfonylurea Compounds/metabolism

Chemicals

Blood Glucose Hypoglycemic Agents Receptors, Drug Sulfonylurea Compounds Glyburide

Authors & Affiliations

6 authors, click to expand affiliations / ORCID

Geisen K

Hitzel V

Okomonopoulos R

Pünter J

Weyer R

Summ H D

Article Info

Journal

Arzneimittel-Forschung

Abbr.

Arzneimittelforschung

ISSN

0004-4172

Published

1985-00-00

Pages

707-12

Language

English

Region

Germany

NLM ID

0372660

Subset

External Links

PubMed source View journal details

Analysis Services

Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.

Contact

WeChat Official Account